Morningstar research shows growing role for CROs and CDMOs

With demand for outsourcing continuing to
increase, US financial services firm Morningstar has published
a
report into the
industry landscape, outlining the increasingly central role that
the sector plays in drug and biologic development.

Major pharma and biotech companies have

for some time relied
on contract research organizations (CROs) and contract
development and manufacturing organizations (CDMOs) to assist
with drug discovery, development and manufacturing.

…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source